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Abstract
The genus of Nocardia is rapidly expanding and the species distribution varies with different geographical locations. We retrospectively
reviewed the laboratory records of the bacteriology laboratory at National Taiwan University Hospital from January 1998 to June 2008
to identify patients with nocardiosis. During the study period, 164 isolates of Nocardia spp. were identiﬁed from 134 patients but only
113 patients had Nocardia infection. Nocardia brasiliensis (n = 54) was the most common pathogen, followed by N. asteroides (n = 36),
N. farcinica (n = 7), N. ﬂavorosea (n = 4), N. otitidiscaviarum (n = 3), N. nova (n = 3), N. beijingensis (n = 2) and one each of N. puris,
N. jinanensis and N. takedensis. The major types of infection were cutaneous infection (56.6%), pulmonary infection (33.6%) and dissemi-
nated infection (7.1%). Eighty-eight patients received sulfonamide-containing antibiotic and eight of 100 patients with available data on
outcomes died during the episode of nocardiosis. In conclusion, the clinical and microbiological manifestations of Nocardiosis vary with
the different Nocardia species. Accurate identiﬁcation of the species is crucial to make the diagnosis.
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Introduction
Members of the genus Nocardia are associated with the
group of microorganisms known as the aerobic actinomyce-
tes and belong speciﬁcally to the family Mycobacteriaceae.
Nocardia are ubiquitous in the environment and can be found
worldwide as saprophytic components in fresh and salt
water, soil, dust, decaying vegetation, and decaying faecal
deposits from animals [1]. They are Gram-positive and
weakly acid-fast, branching bacteria whose hyphae are often
fragmented to coccobacillary forms [2]. Nocardia species are
facultative intracellular pathogens, and the pathogenesis of
nocardiosis is complicated. Although a large number of spe-
cies have been characterized both phenotypically and geno-
typically within the genus, the genotype remains greatly
heterogeneous and continues to evolve [1]. Several species
have been implicated in human infections, but the geographi-
cal prevalence of each may vary greatly throughout the
world. Some species are more prevalent in geographical
locations with a speciﬁc climate [1].
Nocardiosis is an uncommon bacterial infection with a
wide variety of clinical manifestations in immunocompetent
and immunocompromised patients. The number of cases
reported in the literature is increasing. This might be due to
an absolute increase in the number of immunocompromised
patients but also to improvement in laboratory techniques to
detect nocardiosis. Host resistance to nocardial infection
depends on neutrophils in early lesions and then the
cell-mediated immune response [1]. The most common pre-
disposing factors to opportunistic Nocardia infections are
long-term steroid usage, chronic obstructive pulmonary
disease (COPD), neoplastic disease, and human immunodeﬁ-
ciency virus (HIV) infection [3,4]. Clinical manifestations of
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nocardiosis range from cutaneous infections caused by trau-
matic inoculation in normal hosts to severe pulmonary and
central nervous system diseases in immunocompromised
hosts.
The aim of this study was to assess the species distribu-
tion of Nocardia isolates based on the molecular methods in
a teaching hospital over an 11-year period, and to investigate
clinical manifestations, microbiological characteristics,
response to treatment, and outcome of nocardiosis.
Materials and Methods
Patients and setting
This study was conducted at National Taiwan University
Hospital (NTUH), a 2000-bed tertiary care centre in north-
ern Taiwan. Patients with nocardial infection were identiﬁed
by the Bacteriology Laboratory of NTUH from January 1998
to June 2008. The clinical charts of all patients included in
this study were retrospectively reviewed. Information on
age, gender, underlying immunocompromised conditions
including history of immunosuppressant drug use, corticoste-
roid therapy, diabetes mellitus, COPD, chronic liver disease,
chronic kidney disease, malignancy, organ transplantation,
HIV infection, types of clinical specimen positive for Nocardia
spp. and outcome were analysed.
Deﬁnitions
Disseminated nocardiosis was deﬁned as the isolation of
Nocardia species from specimens from two or more non-
contiguous organs such as lungs, lymph node, skin, brain or
blood. A diagnosis of pulmonary nocardiosis required at least
one positive culture from respiratory samples, and the pres-
ence of clinical symptoms and a new lesion on chest xray
ﬁlm at admission. The respiratory samples included expecto-
rated sputum, endotracheal aspiration, pleural effusion,
bronchoalveolar lavage or lung tissue obtained from biopsy.
Long-term steroid usage was deﬁned as prescription of oral
prednisolone at least 10 mg/day for > 2 months before the
infection episode. Patients who had any one of bronchiecta-
sis, COPD or pneumoconiosis with previous symptoms and
compatible old lesions on chest xray ﬁlms were categorized
as having underlying chronic lung disease. Mortality was
deﬁned as death from all causes during the study episode of
hospitalization.
Bacterial isolates
Identiﬁcation of Nocardia species was based on positive
Gram stain (Gram-positive branching, beaded, and ﬁlamen-
tous bacilli) and positive modiﬁed acid-fast stain results, colo-
nial morphotypes, and conventional biochemical reactions,
including hydrolysis of casein, xanthine, hypoxanthine and
tyrosine. All isolates of identiﬁed and unidentiﬁed Nocardia
species, based on these conventional methods, were further
identiﬁed or conﬁrmed by 16S rRNA gene analysis [5].
Partial sequencing analysis of the 16SrRNA gene of the
isolates was performed using primers Noc1 (5¢-GCTTAA-
CACATGCAAGTCG-3¢) (positions 46–64, Escherichia coli
numbering system) and Noc2 (5¢-GAATTCCAGTCTCCC-
CTG-3¢) (positions 663–680, E. coli numbering system) [5].
The sequences were compared with published sequences in
the 16SrRNA database. The closest matches and GenBank
accession number were obtained. For the isolates causing
disseminated nocardiosis and unusual Nocardia species,
susceptibility testing of the agents used in the patients with
these infections was used. The agar dilution method was
used for susceptibility testing, in accordance with the
guidelines recommended by the NCCLS [6].
Results
Microbiological investigation
A total of 164 Nocardia isolates were identiﬁed from 134
patients during the 11 years. After reviewing the medical
records of these patients, 113 patients were conﬁrmed as
having Nocardial infection. Of 113 episodes of nocardiosis,
N. brasiliensis (n = 54) was the most common pathogen,
followed by N. asteroides (n = 36), N. farcinica (n = 7), N.
ﬂavorosea (n = 4), N. otitidiscaviarum (n = 3), N. nova (n = 3),
N. beijingensis (n = 2) and one each of N. puris, N. jinanensis
and N. takedensis. One isolate was not available for further
identiﬁcation to species level (Table 1). Most of the pulmo-
nary infections were caused by N. asteroides, but N. brasiliensis
caused most of the cutaneous infections. Among patients
with disseminated nocardiosis, N. asteroides was the most
common pathogen, followed by N. farcinica.
Clinical features
The demographical and clinical data of patients and the
annual numbers of nocardiosis cases are summarized in
Table 1 and Fig. 1, respectively. Primary cutaneous Nocardia
infection was the most common presentation in 64 (56.6%)
patients. Nocardia caused pulmonary infection in 38 (33.6%)
patients, disseminated infection in eight (7.1%) brain abscess
in two (1.8%) patients and one patient with acute mastoiditis.
The clinical characteristics of the eight patients with disse-
minated nocardiosis are summarized in Table 2.
All of these patients had pulmonary involvement and
ﬁve of them had brain abscesses. The MICs of trimetho-
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prim/sulfamethoxazole against seven isolates varied, ranging
from 2 to 64 lg/dL, whereas amikacin had the lowest
MICs of 0.25 and 1 lg/mL against two isolates. Seven of
the eight patients received sulfonamide-based therapy and
two patients died during the episode of disseminated no-
cardial infection.
The clinical and microbiological features of 15 cases of
nocardiosis caused by the unusual Nocardia species, including
N. otitidiscaviarum, N. jinanensis, N. ﬂavorosea, N. takedensis,
N. nova, N. beijingensis and N. puris are summarized in
Table 3. All of the 15 pathogens from these cases were
identiﬁed by conventional methods and by 16S rRNA gene
analysis. Nocardia ﬂavorosea caused pulmonary infection in
three immunocompromised patients and cellulitis in one
immunocompetent patient with tattoo wound. Nocardia
nova caused pneumonia in two heart transplant recipients
and empyema thoracis in one patient with autoimmune
disease who was receiving steroid therapy. A gardener with
a history of exposure to soil had cellulitis caused by N. jinan-
ensis. One diabetic patient had N. takdensis cellulitis, but she
did not recall any recent insect bite, injury or wound and
denied any exposure to a soil environment. Only one fatal
case of acute respiratory failure was caused by N. puris.
Trimethoprim/sulfamethoxazole showed good in vitro activi-
ties against most of these unusual isolates, except N. otitidisc-
aviarum (MICs of 16 mg/L). MIC of N. puris isolate to
imipenem was 1 mg/L.
TABLE 1. Clinical manifestations, microbiological characteristics and outcomes of 113 patients with nocardiosis
Variables
No. (%) of all patients
(n = 113)
No. (%) of patients
with pulmonary infection (n = 38)
No. (%) of patients with
cutaneous infection (n = 64)
No. (%) of patients with
disseminated infection (n = 8)
Age, years (mean ± SD) 55.8 ± 19.1 57.5 ± 17.2 54.5 ± 20.7 59.0 ± 17.3
Male:female 79:34 29:9 41:23 6:2
Underlying disease condition
Diabetes mellitus 17 (15.0) 6 (15.8) 8 (12.5) 1 (14.3)
Chronic kidney disease 16 (14.2) 5 (13.2) 6 (9.4) 4 (57.1)
Autoimmune disease 16 (14.2) 7 (18.4) 3 (4.7) 2 (28.6)
Solid cancer 12 (10.6) 4 (10.5) 4 (6.3) 3 (42.9)
Chronic lung disease 11 (9.7) 10 (26.3) 0 (0.0) 1 (14.3)
Chronic liver disease 10 (8.8) 2 (5.3) 6 (9.4) 0 (0.0)
Transplant recipient 10 (8.8) 4 (10.5) 3 (4.7) 2 (28.6)
Haematological cancer 7 (6.2) 3 (7.9) 3 (4.7) 0 (0.0)
Thyroid dysfunction 5 (4.4) 1 (2.6) 4 (6.3) 0 (0.0)
AIDS 3 (2.7) 1 (2.6) 2 (3.1) 0 (0.0)
Receiving immunosuppressant 14 (12.4) 5 (13.2) 5 (7.8) 2 (28.6)
Receiving steroid 23 (20.4) 11 (28.9) 6 (9.4) 2 (28.6)
Mortality 8/100 (8.0) 5/36 (13.9) 1/52 (1.9) 2/8 (25.0)
Nocardia spp.
N. brasiliensis 54 (47.8) 2 (5.3) 52 (81.3) 0 (0.0)
N. asteroides 36 (31.8) 22 (57.9) 7 (10.9) 5 (62.5)
N. farcinica 7 (6.3) 3 (7.9) 0 (0.0) 3 (37.5)
N. ﬂavorosea 4 (3.5) 3 (7.9) 1 (1.6) 0 (0.0)
N. otitidiscaviarum 3 (2.7) 2 (5.3) 1 (1.6) 0 (0.0)
N. nova 3 (2.7) 3 (7.9) 0 (0.0) 0 (0.0)
N. beijingensis 2 (1.8) 2 (5.3) 0 (0.0) 0 (0.0)
N. puris 1 (0.9) 1 (2.6) 0 (0.0) 0 (0.0)
N. jinanensis 1 (0.9) 0 (0.0) 1 (1.6) 0 (0.0)
N. takedensis 1 (0.9) 0 (0.0) 1 (1.6) 0 (0.0)
Nocardia sp.* 1 (0.9) 0 (0.0) 1 (1.6) 0 (0.0)
* The isolate was not available for further identiﬁcation to species level.
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FIG. 1. The annual number of nocardiosis cases from January 1998
to June 2008 according to species of Nocardia (a) and types of infec-
tions (b).
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Brain involvement
A total of 28 patients underwent either computed tomogra-
phy (CT) or brain magnetic resonance imaging (MRI) in this
series. Among them, four patients had positive brain image
ﬁndings with multiple brain abscesses and another three
patients had a solitary brain abscess. The temporal lobe was
the most common site of involvement, followed by the
frontal lobe. Neurological symptoms, including unilateral
weakness, vertigo and incoherent speech, presented in only
four patients.
Treatment and outcomes
Eighty-eight patients a received sulfonamide-containing
antibiotic and 13 received combined medical and surgical
treatment. Medical records adequate to determine outcome
were available in 100 of 113 patients.
The crude mortality rate was 8.0% (8/100), and was low-
est for primary cutaneous infection (1.9%) and highest for
disseminated disease (25.0%).
Discussion
Nocardia are slow-growing organisms that are found exten-
sively worldwide, and the genus Nocardia is rapidly expanding,
with at least 80 species described (http://www.bacterio.
cict.fr/n/nocardia.html) to date. Nocardia asteroides is the
most common Nocardia species associated with human dis-
ease [7,8]; however, some Nocardia species are more preva-
lent in geographical locations with a speciﬁc climate. For
instance, N. brasiliensis is associated with tropical environ-
ments and often observed in the southern USA [9–11].
Nocardia farcinica has been reported more frequently in wes-
tern European countries [12,13]. This study of 113 patients
was performed in a subtropical area where N. brasiliensis is
the most common nocardial pathogen, followed by N. asteroides
and N. farcinica. Previous studies [1,14–16] showed that
pulmonary nocardiosis is the most common nocardial
disease, especially in immunocompromised hosts. However,
during the 11-year period of this survey, we found that
primary cutaneous nocardiosis was the most common
presentation of all Nocardia infections, followed by pulmonary
involvement. These differences among study ﬁndings could
be entirely due to geographical variations in Nocardia spp.
distribution. Nocardia brasiliensis was the most common
pathogen in this study and the majority of primary cutaneous
nocardiosis cases were caused by N. brasiliensis.
Identiﬁcation of clinical isolates beyond the genus level is
important since Nocardia species differ in the clinical spec-
trum of the disease they cause and their susceptibility to
antibiotics [17]. After presumptive identiﬁcation, ﬁnal
determination is now accomplished in reference labs using
molecular techniques, such as 16S rRNA sequence analysis.
This study reports the ﬁrst isolates of N. ﬂavorosea, N. nova,
N. puris, N. beijingensis, N. jinanesis and N. takedensis
from Taiwan, and these rare strains caused pulmonary and
cutaneous infections in 15 patients.
Nocardia ﬂavorosea was originally isolated from soil by
Chun et al. in 1998 [18]. To the best of our knowledge, this
is the ﬁrst reported case series of human infection with
N. ﬂavorosea. It caused nocardiosis in three immunocompro-
mised patients with pulmonary infection and another immu-
nocompetent woman with tattoo wound infection. Though
optimal therapy for N. ﬂavorosea infection has not been
TABLE 2. Summary of clinical characteristics and outcome of eight patients with disseminated nocardial infection
No.
(year)
Age
years/sex
Underlying diseases
or condition
Sites of
infection
Nocardia
species
GenBank
(accession no.)
Specimens
of isolate
Antimicrobial
therapy
(MIC, lg/mL) Outcome
1. (2000) 31/F Renal transplant, SLE,
Immunosuppres
sant, and steroid therapy
Lung, brain N. asteroides Sputum, brain SXT (2) Survived
2. (2001) 72/M Chronic obstructive
pulmonary disease
Lung, brain N. asteroides Lung aspirate SXT (8), MIN Survived
3. (2001) 61/M Chronic kidney disease,
renal transplant,
immunosuppressant treatment
Lung, Lymph node N. asteroides Sputum, neck
lymph node
SXT (4) Survived
4. (2003) 68/F Diabetes mellitus, chronic
kidney disease
Lung, brain N. asteroides Sputum, lung
aspirate
Cefpime + AM (0.25),
SXT (4)
Survived
5. (2003) 70/M Gastric cancer Lung, brain N. asteroides Sputum Cefpime + AM (1),
SXT (64)
Survived
6. (2004) 68/M ESRD, ITP with splenectomy,
colon cancer, steroid therapy
Lung, brain N. farcinica EU417670.1 Sputum, blood MEP (4) + SXT (4);
SXT(4)
Survived
7. (2004) 32/M Oral cavity cancer Lung, blood N. farcinica EU417670.1 Sputum, blood MEP (4), SXT (4) Died (1 month
after diagnosis)
8. (2007) 70/M Bronchiectasis,
Sjo¨gren’s disease,
steroid therapy
Lung, blood N. farcinica EU417670.1 Sputum, blood TZP Died (2 days
after diagnosis)
AM, amikacin; MEP, meropenem; MIN, minocycline; SXT, trimethoprim-sulfamethoxazole; TZP, piperacillin/tazobactam.
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established, all four patients responded well to sulfonamide
treatment. Nocardia jinanensis, a novel species, was ﬁrst iso-
lated from soil samples [19], but its clinical signiﬁcance was
unknown. Here we report the ﬁrst case of N. jinanensis
cellulitis in a gardener, who was thought to be infected
because of soil contact. In 2003, a new species of Nocardia,
N. puris, was described and isolated from a human abscess in
Germany [20]. Three years later in Japan, the second strain
of N. puris was isolated from an 81-year-old man with chor-
oiditis [21]. Here, we report the third case of N. puris, which
was recovered from endotracheal aspirates and caused a
fatal pneumonia in a patient receiving steroids. Nocardia
takedensis was recently isolated from a sediment sample
taken from the moat surrounding Takeda Shrine and only
one case of human infection, without a detailed clinical
description, has been reported, by Watanabe et al. [22]. We
report the second case of human infection by N. takedensis,
which was isolated from a biopsy of foot tissue. The portal
of entry of the organism in our patient was not easily
clariﬁed because of the absence of any recent contact history
or environmental conditions suitable for propagation of the
organism. We supposed that the organism might have gained
access via a contaminated trivial cutaneous lesion. Our
results are consistent with previous reports [22,23] that
N. nova can cause opportunistic infection in transplant recipi-
ents and cancer patients, but thoracic empyema due to
N. nova has never been reported.
Our report suggests that the clinical manifestations of
N. nova are protean among severely immunocompromised
patients. Wang et al. [24] ﬁrst isolated N. beijingensis from
soil in China in 2001 and Kageyama et al. [25] reported this
new species in human infectious samples in 2004. Here, we
report two cases of pulmonary infection due to N. beijingensis,
and both patients improved after treatment with trimetho-
prim/sulfamethoxazole. However, it is believed that some of
these unusual Nocardia species are widely distributed in
South-East Asia, including China and Japan [21]. Therefore,
diseases caused by these microorganisms may be underre-
ported. Because of the diversity of Nocardia species, accurate
identiﬁcation is imperative before proper treatment can be
determined. Studies of more clinical isolates are needed to
decipher the spectrum of clinical diseases caused by these
rare pathogens.
Disseminated nocardiosis has been rarely reported [14–
16,26,27]; eight cases were identiﬁed in our study. In most
of these cases the patients were immunocompromised and
TABLE 3. Summary of clinical characteristics and outcomes of 15 patients with nocardiosis caused by unusual Nocardia
species
No. of
patient
(year)
Age
(years)/
sex
Underlying diseases
or condition
Nocardia
species
GenBank
(accession no.)
Clinical
diagnosis Site of isolate
Antimicrobial
therapy
(MIC, lg/mL) Outcome
1. (1999) 73/M Nil N. jinanensis DQ462650.1 Cellulitis Skin pus SXT (4) Improved
2. (1999) 29/M AIDS N. ﬂavorosea EU841599.1 Pneumonia Sputum SXT (4) Improved
3. (1999) 68/F Chronic kidney disease,
diabetes mellitus
N. takedensis AB156277.1 Cellulits Skin pus SXT (4) Improved
4. (2000) 58/M Heart transplant,
immunosuppressant therapy
N. nova DQ840026.1 Pulmonary
infection
Lung aspirate SXT (8) Improved
5. (2001) 64/M Heart transplant
immunosuppressant therapy
N. nova DQ840026.1 Pulmonary
infection
Lung biopsy SXT Improved
6. (2002) 66/M Autoimmune haemolytic
anaemia, steroid therapy,
chronic hepatitis C,
diabetes mellitus
N. nova DQ840026.1 Empyema Pleural effusion SXT + CIP +
VATS decortication
Improved
7. (2003) 21/M Immunosuppressant therapy,
dermatomyositis
N. beijingensis DQ659901.1 Pneumonia Sputum SXT (4) Improved
8. (2004) 75/F Bronchiectasis N. beijingensis DQ659901.1 Pulmonary
infection
Sputum SXT (4) Improved
9. (2004) 81/M Idiopathic pulmonary ﬁbrosis,
steroid therapy
N. puris AB097455.1 Pulmonary
infection
Endotracheal aspirate Imipenem (1) Died
10. (2005) 51/M Nil N. otitidiscaviarum DQ659912.1 Pulmonary
infection
Bronchial
washing and sputum
SXT (16) Improved
11. (2005) 34/F Tattoo wound N. ﬂavorosea EU841599.1 Cellulitis Skin pus SXT (4) Improved
12. (2005) 63/M Steroid therapy,
chronic kidney disease
N. ﬂavorosea EU841599.1 Pulmonary
infection
Lung aspirate SXT (4) Improved
13. (2006) 89/M Lung cancer, chronic
pulmonary
obstructive disease
N. otitidiscaviarum DQ659912.1 Pulmonary
infection
Bronchial
washing and sputum
SXT (16) Died
14. (2007) 79/M Nil N. otitidiscaviarum DQ659912.1 Cutaneous
infection
Skin pus Unknown Unknown
15. (2008) 84/M Chronic myelogenous
leukaemia, chronic
pulmonary
obstructive disease,
steroid therapy
N. ﬂavorosea EU841599.1 Pulmonary
infection
Sputum SXT (4) Improved
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the infections were caused by N. asteroides. All of these
cases had pulmonary involvement, which, not surprisingly,
accounted for the origin of the dissemination. Although ﬁve
patients had brain abscesses, three patients did not have a
focal neurological or meningeal sign. Although disseminated
nocardiosis is supposed to occur via haematogenous spread,
only two patients had a blood culture positive for Nocardia.
All eight patients received trimethoprim/sulfamethoxazole-
based therapy, and only two cases with nocardial bactera-
emia died, despite the wide range of MICs of trimethoprim/
sulfamethoxazole in the in vitro study. Further clinical studies
are needed to establish the relationship between in vitro
susceptibility and in vivo results. Furthermore, our ﬁndings
suggest the importance of brain imaging and blood culture
for the diagnosis of disseminated nocardiosis, especially in
immunocompromised patients.
In this study, isolated brain abscess was found in two
patients; one of these infections was caused by N. farcinica and
the other by N. asteroides. Five of the eight patients with dis-
seminated infection had brain involvement. In fact, 28 patients
had previously undergone brain CT or MRI when pulmonary
nocardial infection was diagnosed. Among them, four patients
had neurological symptoms but another three patients with
nocardial brain abscess did not have any neurological deﬁcits.
These ﬁndings suggest that brain imaging should be performed
routinely in patients with pulmonary nocardiosis to detect
possible brain abscess even in asymptomatic patients.
Acute mastoiditis is an uncommon complication of otitis
media and is rarely caused by Nocardia spp. [28,29]. Most of
the reported cases of acute mastoiditis [28,29] occurred in
immunocompromised patients. One patient in this study, a
37-year-old man with nasopharyngeal carcinoma who had
received concurrent chemo-radiotherapy, developed N. aster-
oids-related acute mastoiditis. The infection was cured by tri-
methoprim/sulfamethoxazole monotherapy. Although this
clinical entity is extremely rare, it may have a fatal outcome
by evolving into a brain abscess [28].
In conclusion, nocardiosis is not rare in Taiwan. It is
a protean disease that manifests with different clinical and
microbiological features depending on the infecting Nocardia
species. Therefore, accurate identiﬁcation of Nocardia species
using molecular techniques is important to make the
diagnosis and to elucidate the epidemiology. Fortunately, our
ﬁndings indicate that a sulfa-containing regimen remains
effective in treating nocardial infection.
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